Shares Magazine
21.25p+1.25 (+6.25%)17 Apr 2025, 16:12
Jump to:
Skinbiotherapeutics PLC Fundamentals
| Company Name | Skinbiotherapeutics PLC | Last Updated | 2025-04-17 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 231.975 m | Market Cap | £49.29 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.02 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.1407 | Debt Equity Ratio | 0.2176 |
| Asset Equity Ratio | 1.6259 | Cash Equity Ratio | 0.2756 |
| Quick Ratio | 1.2144 | Current Ratio | 1.79 |
| Price To Book Value | 10.9890 | ROCE | 0 |
Skinbiotherapeutics PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Skinbiotherapeutics PLC Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | £116,369.00 | £173,160.00 | £126,903.00 |
| Intangible Assets | £3.43 m | £700,331.00 | £625,504.00 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £3.54 m | £873,491.00 | £752,407.00 |
| Stocks | £472,419.00 | £33,497.00 | £122,571.00 |
| Debtors | £341,154.00 | £13,509.00 | £12,901.00 |
| Cash & Equivalents | £800,904.00 | £1.31 m | £1.80 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £5.22 m | £2.59 m | £3.08 m |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | £1.80 m | £529,741.00 | £508,959.00 |
| Creditors after 1 year | £440,485.00 | £69,601.00 | £100,647.00 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £2.25 m | £599,342.00 | £609,606.00 |
| Net assets | £2.97 m | £1.99 m | £2.48 m |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | £2.02 m | £1.73 m | £1.57 m |
| Share Premium | £14.51 m | £10.95 m | £8.76 m |
| Profit / Loss | -£2.95 m | -£3.01 m | -£2.99 m |
| Other Equity | £2.97 m | £1.99 m | £2.48 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £2.97 m | £1.99 m | £2.48 m |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | £0.01 | £0.03 | £0.04 |
| Debt-to-Equity | £0.01 | £0.03 | £0.04 |
| Assets / Equity | 1.6259 | 1.6259 | 1.6259 |
| Cash / Equity | 0.2756 | 0.2756 | 0.2756 |
| EPS | -£0.02 | -£0.02 | -£0.02 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | -£2.73 m | -£2.65 m | -£2.67 m |
| Cashflow before financing | £1.79 m | -£327,812.00 | -£2.71 m |
| Increase in Cash | -£510,930.00 | -£493,089.00 | -£2.80 m |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | £1.21 m | £132,057.00 | £74,761.00 |
| Cost of sales | £525,631.00 | £46,867.00 | £29,424.00 |
| Gross Profit | £683,038.00 | £85,190.00 | £45,337.00 |
| Operating Profit | -£2.91 m | -£3.00 m | -£2.98 m |
| Pre-Tax profit | -£2.95 m | -£3.01 m | -£2.99 m |
Skinbiotherapeutics PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema. |
| Latest Interim Date | 26 Mar 2025 |
| Latest Fiscal Year End Date | 4 Dec 2024 |
Skinbiotherapeutics PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2022-04-29 | Mr. Douglas John Quinn | Executive Director,Chief Financial Officer and Company Secretary |
| 2024-12-10 | Mr. Martin Braddock Hunt | Non-Executive Director,Chairman |
| 2020-12-04 | Dr. Catherine Anne O'Neill | Executive Director,Chief Executive Officer |
| 2024-12-10 | Dr. Catherine Denise Prescott | Non-Executive Director |
| 2024-12-10 | Mr. Stuart John Ashman | Executive Director,Chief Executive Officer |
| 2024-12-10 | Mr. Manprit Singh Randhawa | Executive Director,Chief Financial Officer and Company Secretary |
| 2024-12-10 | Ms. Danielle Bekker | Non-Executive Director |
Skinbiotherapeutics PLC Contact Details
| Company Name | SkinBioTherapeutics PLC |
|---|---|
| Address | 15 Silk House, Park Green, Macclesfield, SK11 7QJ |
| Telephone | +44 1614682760 |
| Website | https://www.skinbiotherapeutics.com |
Skinbiotherapeutics PLC Advisors
| Auditor | Jeffreys Henry LLP |
|---|---|
| Phone | +44 2073092222 |
| Fax | +44 2073092309 |
| Financial PR Adviser | Instinctif Partners |
|---|---|
| Phone | +44 2074572020 |
| Fax | +44 2078667900 |
| Solicitor | turnerparkinson LLP |
|---|
| Registrar | Share Registrars Limited |
|---|---|
| Phone | +44 1252821390 |
| Fax | +44 1252719232 |
| Nominated Adviser | Cairn Financial Advisers LLP |
|---|---|
| Phone | +44 2072130880 |
| Stockbroker | Turner Pope Investments (TPI) Ltd |
|---|---|
| Phone | +44 2036214120 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Dunelm Group PLC | 1,074.00 | 13.29 |
| Asos PLC | 313.50 | 6.63 |
| Rentokil Initial PLC | 350.00 | 5.01 |
| Sainsbury (J) PLC | 256.80 | 3.55 |
| Dr. Martens PLC | 52.80 | 3.53 |
| Pershing Square Holdings LTD | 3,414.00 | 3.45 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Dowlais Group PLC | 51.40 | -6.03 |
| Fresnillo PLC | 1,021.00 | -5.55 |
| Jupiter Fund Management PLC | 69.30 | -5.07 |
| Goodwin PLC | 6,780.00 | -4.51 |
| Spectris PLC | 1,987.00 | -4.38 |
| Twentyfour Income Fund Limited | 108.60 | -3.89 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.